• Profile
Close

Effects of zoledronate on cancer, cardiac events, and mortality in osteopenic older women

Journal of Bone and Mineral Research Oct 25, 2019

Reid IR, Horne AM, Mihov B, et al. - Researchers conducted this prospective, randomized, placebo-controlled, double-blind trial to analyze the impact of zoledronate on cancer, cardiac events, and mortality in older women with osteopenia. Participants in the study were randomized to receive four infusions of either zoledronate 5 mg or normal saline at 18-month intervals. In all, there were 1,017 serious adverse events among 443 candidates in the placebo group and 820 events in 400 candidates in zoledronate treatment group. These events included fractures leading to admission to the hospital. In 39 women in the placebo group and in 24 women in the zoledronate treatment group, myocardial infarction occurred. Total cancers with zoledronate were significantly decreased, which was significant for both breast and non-breast cancers. Data reported that the HR for death was 0.65, and 0.51 in those without incident fragility fracture. The investigators found that these beneficial effects warrant more adequately powered zoledronate trials as primary endpoints with these nonskeletal conditions.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay